Prologue. Revolution, transition, and transformation -- Medical profession sovereignty to protect and promote the science and evidence base of US medicine -- US integration of government, academia, and industry : a catalyst for science-technology revolutions -- The proliferation of US direct-to-consumer (DTC) and direct-to-physician (DTP) biopharmaceutical marketing -- The evolution of consumer genetic testing services from Oncormed, Inc. to 23andMe Holding Co. -- Vulnerability of the science and evidence base of US medicine -- A warning label for commercial direct-to-consumer (DTC) genetics -- Protecting and promoting the evidentiary-science base of personal genome medicine (PGM) epilogue. the personal genome future of US medicine.
Summary:
"The United States' decentralized, largely privatized, and commerce-driven healthcare system is undergoing a shift to personal genome medicine. This change is charged by ongoing progress in biotech and genomic research and development. This book draws from U.S. medicine's past and present to address its emerging personal genome medicine future"-- Provided by publisher.
This resource is supported by the Institute of Museum and Library Services under the provisions of the Library Services and Technology Act as administered by State Library of Iowa.